Finally, we directly examined the predictive value of PLA2G2D expression for patient response to ICB therapy in melanoma and urothelial carcinoma immunotherapy cohorts, given the lack of transcriptional data in CSCC immunotherapy cohorts. Here, PLA2G2D is linked to melanoma.